The NewsYet – Drug delays type 1 diabetes in people at high risk: Study – Greater Kashmir
The NewsYet –
In a first, scientists have developed a treatment that can delay type 1 diabetes by two or more years among people who are at high risk.
The research, published in the New England Journal of
Medicine, involved treatment with an anti-CD3 monoclonal antibody (teplizumab).
Researchers from Yale University in the US enrolled 76
participants ages 8-49 who were relatives of people with type 1 diabetes, had
at least two types of diabetes-related autoantibodies (proteins made by the
immune system), and abnormal glucose (sugar) tolerance.
Type 1 diabetes develops when the immune system’s T cells
mistakenly destroy the body’s own insulin-producing beta cells. Insulin is
needed to convert glucose into energy. Teplizumab targets T cells to lessen the
destruction of beta cells.
“Previous clinical research found that teplizumab
effectively slows the loss of beta cells in people with recent onset clinical
type 1 diabetes, but the drug had never been tested in people who did not have
clinical disease,” said Kevan C Herold, of Yale University.
Faster progression of type 1 diabetes is associated with a
highly active immune system, which may explain the impact of immune
system-modulating drugs like teplizumab.
The research team also cautioned that the study
had limitations, including the small number of participants, their lack of
ethnic diversity, and that all participants were relatives of people with type
1 diabetes, potentially limiting the ability to translate the study broadly.